Currently, BRAF inhibitors in combination with MEK inhibitors are applied for treating melanoma since about 50% of non-acral melanomas possess mutated BRAF (mainly BRAFV600E), which causes aberrant activation of the downstream mitogen-activated protein kinase (MAPK) signals, leading to the proliferation of cancer cells [12–17]. This evidence concerns the gene WNK2 and melanoma.